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Objective: To determine the efficacy of weekly treatment with oral azithromycin for 13 weeks on the
severity and resolution of reactive arthritis (ReA).
Methods: 186 patients from 12 countries were enrolled in a randomised, double blind, placebo controlled
trial. Inclusion criteria were inflammatory arthritis of (6 swollen joints, and disease duration of
(2 months. All patients received a single azithromycin dose (1 g) as conventional treatment for possible
Chlamydia infection, and were then randomly allocated to receive weekly azithromycin or placebo.
Clinical assessments were made at 4 week intervals for 24 weeks.
Results: 152 patients were analysable (34 failed entry criteria), with a mean (SD) age of 33.8 (9.4) and
duration of symptoms 30.7 (17.5) days. Mean C reactive protein (CRP) was 48 mg/l, and ,50% of those
typed were HLA-B27+, suggesting that the inclusion criteria successfully recruited patients with acute ReA.
Treatment and placebo groups were well matched for baseline characteristics. There were no statistical
differences for changes in any end point (swollen and tender joint count, joint pain, back pain, heel pain,
physician and patient global assessments, and CRP) between the active treatment and placebo groups,
analysed on an intention to treat basis or according to protocol completion. The time to resolution of
arthritis and other symptoms or signs by life table analyses was also not significantly different. Adverse
events were generally mild, but were more commonly reported in the azithromycin group.
Conclusions: This large trial has demonstrated that prolonged treatment with azithromycin is ineffective in
ReA.
R
eactive arthritis (ReA) is an inflammatory monarthritis
or asymmetric oligoarthritis usually lasting for a few
weeks. It is associated with previous infection, mainly of
the genitourinary or gastrointestinal tract.1 The most fre-
quently identified triggering infections are Chlamydia tracho-
matis or Ureaplama urealyticum, causing urethritis, and
Salmonella, Yersinia, Shigella, or Campylobacter species causing
gastroenteritis. These bacteria are obligate or facultative
intracellular pathogens. However, in about half of the
patients presenting with arthritis suggestive of ReA no
triggering infection is found,2 although an asymptomatic
infection is certainly capable of triggering arthritis. Several
lines of evidence suggest that ReA is associated with an
immunological response to the above bacteria, characterised
by the increased level and prolonged presence of serum
antibodies3 4 and of synovial T cells from affected joints
proliferating in vitro to the bacterial antigens.5–7 Several
observations indicate the presence of Chlamydia trachomatis
antigens or related DNA and RNA sequences in synovial
samples of patients with ReA.8–11 Antigens from Gram
negative organisms have also been identified in synovium
and synovial fluid, mainly within phagocytic cells,12–14 but
nucleic acids have been found only rarely.15–17 Nevertheless,
the weight of evidence clearly suggests that bacterial antigens
and/or viable bacteria do reach the affected joints even
though the joints are sterile on culture, indicating that any
viable bacteria are in a non-cultivable state. Furthermore,
bacterial antigens and DNA/RNA have been detected in joints
many months after the initial infection,17 indicating that
persistent infection may be a feature of ReA.
If persistent infection results in the continual delivery of
antigens or organisms to joints where they elicit immune
responses, this might be the principal pathogenic mechanism
responsible for joint inflammation. This in turn raises the
hypothesis that antibiotic treatment may be useful in the
treatment of ReA, because this would eradicate the organism
and allow joint inflammation to settle in the absence of
continued antigen production. A placebo controlled study in
a limited number of patients suggested that, at least for
Chlamydia trachomatis induced arthritis, antibiotics could
reduce the duration and severity of established disease.18
Azithromycin is an azalide antibiotic which penetrates the
cell membranes and concentrates within the lysosomal
compartment. Consequently, it is widely distributed through-
out the body, achieving higher concentrations in tissues and
in a variety of cell types such as phagocytes and fibroblasts
than in blood, with a tissue/serum concentration ratio
ranging from 50 to 1150. In animal models, data indicate
that delivery of biologically available azithromycin to infected
tissue is further enhanced by inflammatory processes.19 20 In
man, the efficacy encompasses the pathogens generally
associated with classical ReA—that is, Chlamydia trachomatis,
Ureaplasma, Salmonella, Shigella, Yersinia, Campylobacter, while
it also has activity against organisms which can be associated
with postinfectious arthritis, such as Streptococcus and
Gonococcus. In patients with acute Chlamydia trachomatis
urogenital infection, a single dose of 1 g of azithromycin
was shown to be as effective as a 7 day course of doxy-
cyline.21 22
Abbreviations: CRP, C reactive protein; DMARDs, disease modifying
antirheumatic drugs; ITT, intention to treat; LCR, ligase chain reaction;
PCR, polymerase chain reaction; ReA, reactive arthritis
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We therefore chose azithromycin to investigate whether a
3 month course of treatment could hasten recovery or
diminish the severity of ReA, or both.
PATIENTS AND METHODS
Study design
The study was a randomised, multicentre, placebo controlled,
double blind study of 12 weeks comparing the efficacy of 1 g
oral azithromycin weekly (two tablets of 500 mg) for
12 weeks versus placebo, starting one week after a 1 g single
dose of azithromycin.
Eligibili ty
Patients between 16 and 55 years presenting with an acute
unexplained inflammatory arthritis were eligible for the
study if the enrolling physician considered the diagnosis of
ReA a reasonable possibility—that is, alternative causes of
acute arthropathy such as septic arthritis, Lyme disease,
crystal arthropathy, and rheumatic fever had been excluded
by routine investigations. Patients in whom joint symptoms
might be attributed to spondyloarthropathies other than ReA
(or undifferentiated spondyloarthropathy), osteoarthritis,
rheumatoid arthritis (including those with rheumatoid
factor), or systemic lupus erythematosus were also excluded,
together with those with trauma or orthopaedic conditions.
Enrolment required duration of symptoms of (2 months
and involvement of (6 single swollen joints. The criteria
intentionally did not require preceding gastrointestinal or
genitourinary symptoms because these are commonly
absent,2 and we wished to recruit a clinically representative
population of patients with ReA.
Criteria for exclusion included pregnancy and lactation,
known hypersensitivity to macrolides or azithromycin, use of
ergotamine or digitalis, an estimated creatinine clearance of
,40 ml/min, and serum values of alanine aminotransferase,
aspartate aminotransferase, and alkaline phosphatase higher
than twice the upper limit. Moreover, patients were excluded
for the following conditions:
N Use of antibiotics for 10 days or more within 30 days
before enrolment
N Administration of corticosteroids (oral, intravenous, intra-
muscular) or disease modifying antirheumatic drugs
(DMARDs) within 2 months before enrolment
N Intra-articular corticosteroid injection within 2 weeks
before enrolment
N Infections requiring antibiotic treatment in addition to the
study drug
N History of peptic ulceration, gastrectomy, or any other
gastrointestinal condition that might affect absorption of
the study drug
N Evidence of drug abuse or alcoholism
N Immunodeficiency from any cause (but known HIV
positive patients could be enrolled, provided that they
had no evidence of being immunosuppressed).
Informed consent
The patient had to give written informed consent in
accordance with the provisions of the pertinent excerpt from
the revised Declaration of Helsinki. Before entry into this
study, each potential study participant was informed of the
nature, duration, and purpose of the study, the methods and
means by which the study drug was to be administered, and
all the potential benefits, inconveniences, and hazards that
might reasonably be expected.
Study description
The study was of 6 months’ duration, including a 12 week
study drug administration period (azithromycin or placebo
after 1 g single dose of azithromycin). To relieve pain and
inflammation patients were allowed to take piroxicam 20 mg
once a day for as long as was needed. Paracetamol, in
addition to piroxicam, was provided for further pain relief.
Patients who were intolerant of piroxicam were allowed to
change to another non-steroidal anti-inflammatory drug. If
oral corticosteroids or DMARDs were required during the
study, the patient was removed from the trial at the time
these drugs were given.
Intra-articular steroids were avoided where possible;
however, if these drugs were required they were permitted
only during monthly visits, and only given after evaluations
were performed and recorded on the case record form. In
cases where injections were given between scheduled visits,
the patients were withdrawn from the study.
Visits were scheduled every 4 weeks for 24 weeks.
Assessments
Outcome measures of disease activity and therapeutic
efficacy were obtained at baseline and every 4 weeks for
24 weeks. Outcome measures included a variety of assess-
ments reported by the patient and clinician.
Patient self assessment measures included overall disease
activity (five point scale: 1=asymptomatic; 2=mild;
3=moderate; 4= severe; 5=very severe) and pain site
assessment (assessment of pain in joints, back, and heels,
each on a five point scale)
Clinical assessment measures included the number of
swollen joints and the number of tender joints using a 56
joint schema (in which dactylitis is counted as one swollen
joint), the presence or absence of enthesopathies at the heel,
the overall disease activity according to a five point scale, and
Table 1 Demographic data and disease characteristics
at baseline (mean (SD) for continuous variables, count (%)
for categorical variables)
Azithromycin Placebo
p Value*(n = 81) (n = 71)
Age (years) 33.0 (9.8) 34.7 (8.9) 0.28
Duration of arthritis (days) 30.1 (17.3) 30.7 (17.9) 0.85
Women 25 (31) 24 (34) 0.70
Previous similar episode 17 (21) 15 (21) 0.92
Recent intra-articular steroid
injection
20 (25) 17 (24) 0.98
Heel enthesopathy 28 (35) 30 (42) 0.33
Urethritis (symptom) 13 (16) 12 (17) 0.86
Diarrhoea (symptom) 5 (6) 2 (3) 0.33
Skin abnormalities 11 (14) 10 (14) 0.93
Eye abnormalities 17 (21) 14 (20) 0.85
Genitourinary abnormalities 19 (24) 17 (24) 0.97
HLA-B27 22 (63) 12 (41) 0.09
*Two sample t test. azithromycin—35 patients and placebo—30
patients tested.
Table 2 Reasons for termination of the study (counts (%))
Azithromycin Placebo
(n = 81) (n = 71)
No or insufficient response treatment 5 (6) 4 (6)
Laboratory abnormalities 1 (1) 1 (1)
Adverse events 3 (4) 2 (3)
Patient’s request 3 (4) 3 (4)
Investigator’s decision 6 (7) 11 (15)
Intra-articular corticosteroid injections 1 (4) 1 (1
Other 4 (5) 1 (1)
Completed study 57 (70) 47 (66)
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presence of extra-articular manifestations (conjunctivitis,
keratoderma, oral ulcers).
Laboratory evaluations at each visit included CRP, serum
alanine aminotransferase, aspartate aminotransferase, alka-
line phosphatase, and creatinine; haemoglobin, packed cell
volume, white blood cell count with differential, and platelets
were also measured. CRP was measured both at each study
site and at a central laboratory.
Urine samples were collected at each visit, stored at 220 C˚,
and analysed by ligase chain reaction (LCR) for the presence
of Chlamydia trachomatis DNA. These tests, together with
measurements of CRP, rheumatoid factor, and HLA-B27
status were each performed at a single laboratory.
Patients were screened for adverse drug reactions and
intercurrent illnesses at every visit.
Data collection and analyses
The primary efficacy measures were physician assessment of
disease activity, patient assessment of disease activity,
number of swollen and number of tender joints, and time
Table 3 Mean (SD) changes in disease activity measures from baseline to 24 weeks (ITT, last observation carried forward) in
the azithromycin and placebo groups
Azithromycin (n = 81) Placebo (n = 71)
Treatment effectBaseline* Change Baseline* Change
Physician global 2.06 (0.71) 1.11 (0.86 to 1.36) 2.00 (0.70) 1.21 (0.98 to 1.44) 0.10 (20.24 to 0.44)
Patient global 2.11 (0.72) 1.14 (0.87 to 1.41) 2.06 (0.77) 1.18 (0.94 to 1.43) 0.04 (20.32 to 0.42)
Joint pain 2.20 (0.73) 1.32 (1.06 to 1.59) 1.99 (0.84) 1.23 (0.96 to 1.49) 20.09 (20.47 to 0.30)
Back pain 0.52 (0.85) 0.38 (0.19 to 0.57) 0.38 (0.72) 0.21 (0.03 to 0.39) 20.17 (20.43 to 0.09)
Heel pain 0.62 (0.98) 0.33 (0.12 to 0.55) 0.73 (1.00) 0.35 (0.09 to 0.61) 0.02 (20.31 to 0.35)
Swollen joint count 2.63 (1.53) 1.44 (0.95 to 1.94) 2.25 (1.28) 1.44 (1.01 to 1.86) 20.01 (20.66 to 0.64)
Tender joint count 3.69 (3.31) 1.79 (0.92 to 2.65) 3.52 (3.45) 1.76 (0.87 to 2.65) 20.03 (21.26 to 1.21)
CRP 43 (49) 25 (11 to 38) 47 (55) 35 (20 to 50) 10.0 (29.6 to 30.5)
CRP centrally measured 60 (51) 47 (30 to 64) 38 (55) 32 (12 to 52) 215.0 (240.0 to 11.0)
*No significant difference between baseline values; mean (95% CI) difference (placebo minus azithromycin) between 24 week changes in disease activity
measures.
Figure 1 Time dependent improvement of six important end point measures in the completer population (mean (95% CI)): (A) tender joint count; (B)
swollen joint count; (C) joint pain; (D) CRP; (E) patient global assessment; (F) physician’s global assessment.
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to resolution of arthritis, defined as the absence of joint
swelling and time to disappearance of pain. Secondary
efficacy parameters were the number of patients dropping
out from the study owing to lack of efficacy (defined as a
patient needing treatment with oral corticosteroids or
DMARDs) and changes in other clinical and laboratory
measures. The major comparison was between the rando-
mised groups treated with azithromycin or placebo.
Data were collected on appropriate case record forms and
entered into the database by one of the authors (P-AP), who
also performed the clarification of the data files (collection of
missing data from investigators; correction of incorrect data
and inconsistencies). Patients not fulfilling the inclusion and
exclusion criteria were excluded from the analyses. Data were
analysed in the patient population receiving at least one dose
of the trial drug (intention to treat (ITT)) and in those
completing the entire 24 week study period (completer
population). For the ITT analyses the last observation was
projected forward to the subsequent missing measurement
points.
Summary statistics were used for presentation of demo-
graphic and disease variables (mean or median for contin-
uous variables, and counts (percentages) for categorical
variables). Efficacy was analysed by comparing the azithro-
mycin and placebo groups in three different ways: t tests for
changes from baseline to the end of the study, and repeated
measurements analysis of variance for time dependent
changes during the study. Kaplan-Meier survival analyses
and log rank tests were used to analyse the time to resolution
of arthritis and other end points.
RESULTS
The number of patients originally enrolled was 186, but 34
were excluded for the following reasons: no swollen joint at
baseline (n=5), swollen joint count .6 (n=11), not
fulfilling all inclusion criteria (n=1), one or more exclusion
Figure 2 Time to resolution of signs and symptoms (Kaplan-Meier survival analyses). (A) no tender joints; (B) no swollen joints; (C) no joint pain; (D)
CRP ,10 mg/l; (E) patient global assessment asymptomatic; (F) physician’s global assessment asymptomatic.
Table 4 Number (%) of patients reporting adverse
events within various organ systems during the study
Azithromycin Placebo
p Value*(n = 81) (n = 71)
Gastrointestinal 30 (37) 12 (17) 0.006
Fungal infections 2 (2) 1 (1) 0.64
Respiratory 10 (12) 9 (13) 0.95
Cutaneous 5 (6) 3 (4) 0.59
Stomatitis 2 (2) 1 (1) 0.64
Neurological 2 (2) 1 (1) 0.64
Headache 3 (4) 0 0.10
Urogenital 1 (1) 2 (3) 0.48
Laboratory abnormalities 1 (1) 3 (4) 0.25
Miscellaneous 13 (16) 10 (14) 0.60
*x2 Test.
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criteria present (n=3), duration of symptoms >60 days
(n=10), missing information on swollen joint count or
duration of symptoms (n=4), positive rheumatoid factor test
(n=3) (some patients had more than one reason for being
excluded).
The mean (SD) age of the 152 patients fulfilling the
inclusion and exclusion criteria was 33.8 (9.4) years, disease
duration was 30.4 (17.5) days, and 49 (32%) were female.
The patients were recruited from 12 different European
countries (Austria (n=6), Bulgaria (n=13), Denmark
(n=15), Finland (n=26), France (n=17), Germany
(n=8), Hungary (n=1), Lithuania (n=25), Norway
(n=15), Slovakia (n=3), The Netherlands (n=9), and
United Kingdom (n=14)).
The demographic variables and disease characteristics at
baseline of the azithromycin and placebo groups were compar-
able (table 1). Fifty seven (70%) of the azithromycin group
and 47 (66%) of the placebo group completed the 24 weeks of
the trial. No major differences in the reasons for withdrawal
were seen between the treatment groups (table 2).
Improvement was seen in both the azithromycin and
placebo groups, with favourable changes across all measures
of disease activity. However, the changes were of similar
magnitude, and statistically significant differences were not
observed for any end point in the ITT population (table 3).
Similar results were obtained in the completer population
(data not shown).
The improvement was seen early after randomisation.
Figures 1A–F show the mean scores for six important end
points (tender and swollen joint count, joint pain, CRP, and
patient and physician global assessments) in the completer
population. The time dependent improvement was similar for
both treatment groups and no differences were seen when
the groups were compared statistically by repeated measure-
ments analysis of variance. Similar results were seen in the
ITT population (data not shown).
Time to resolution of arthritis (no joint tenderness, no joint
swelling), to resolution of joint pain, to achieving CRP ,10
mg/l, and to zero activity on the patient and physician global
assessments were compared by life table analyses (figs 2A–
F). No differences were found between the treatment groups
for the time to achieve these treatment successes—both in
the ITT (figs 2A–F) and completer population (data not
shown).
Adverse events were more frequently reported in the
azithromycin group than in the placebo group (table 4).
The numbers of patients reporting adverse events during the
first 4 weeks were 30 in the azithromycin and 13 in the
placebo groups (p=0.01), 25 versus 9 during the subsequent
4 week period (p=0.01), and 18 versus 7 during the last
4 weeks receiving active drug treatment (p=0.07). No
differences in reported adverse events were seen during the
observation period. Adverse events were generally mild and
did not lead to any group difference in withdrawal rate
(table 2). Adverse events in the azithromycin group were
most frequently reported from the gastrointestinal system
(table 4).
It was initially planned to analyse data from patients
positive for infection with Chlamydia. However, Chlamydia
infection was only detected in 12/130 patients in whom urine
was tested by LCR. All these patients were LCR negative after
treatment, indicating that administration of the single dose
of azithromycin was effective in those who otherwise
received placebo. This cohort was too small for assessment
of clinical outcome.
DISCUSSION
There have been several trials of prolonged antibiotic
treatment in the treatment of ReA.18 23–26 Most of these have
shown that antibiotics have no beneficial effect; a notable
exception is the trial by Lauhio et al, in which treatment with
lymecycline decreased the duration of ReA due to Chlamydia
infection.18 However, this finding arose out of a subgroup
analysis of the cohort of patients recruited to the study and
the trial included somewhat smaller numbers. Effective
treatment with antibiotics for chronic yersiniosis has also
been reported,27 28 but many of these patients had other
disease manifestations such as lymphadenopathy rather than
classical ReA. The most convincing evidence for the effec-
tiveness of antibiotic in ReA comes from the study of Bardin
et al in Greenland,29 but in that study antibiotics were not
used to hasten resolution of arthritis, but prophylactically to
decrease the incidence of sexually acquired infection in a
population predisposed to develop ReA. A recent report also
suggested that patients treated with ciprofloxacin for
Salmonella gastroenteritis had a diminished risk of developing
ReA or other musculoskeletal complications.30 Additionally, a
follow up analysis of an originally negative placebo controlled
trial on the efficacy of ciprofloxacin in acute reactive
arthritis26 indicated that a 3 month course with antibiotics
in the acute phase might have a beneficial effect on the long
term prognosis.31
Previous trials have adopted different recruitment policies,
with some restricted to disease of short duration and others
including those with chronic disease. In addition the
evidence required to make a diagnosis of ReA also varies in
different studies. In the absence of agreed classification
criteria for ReA,32 selection of the patients for inclusion in
clinical trials presents significant problems. If positive culture
of the triggering organism is demanded for inclusion many
cases of ReA will be excluded, and there would be significant
difficulty in accumulating large numbers of these patients in
a short time. Likewise insistence on preceding gastrointest-
inal or genitourinary symptoms excludes some patients with
undoubted ReA.2 The policy of the current trial was to recruit
patients with acute disease ((2 months), and (6 swollen
joints. This six joint cut off point was chosen as an expert
decision. Although ReA may be polyarticular, this is relatively
unusual and the upper limit of six affected joints made it less
likely that patients with early rheumatoid arthritis would be
included. Further, serum samples were reanalysed after the
study for presence of rheumatoid factor, which led to the
exclusion of three patients. Within ReA and related diseases
it has been widely accepted that patients can be classified
according to their clinical presentation—for example, as
spondyloarthropathy. Actually, the patients in this study also
fulfilled the European Spondylarthropathy Study Group
criteria for spondyloarthropathy.33 Thus, an alternative to
the term ReA in this study might be undifferentiated acute
spondyloarthropathy.
One limitation of the present study is the lack of
comprehensive examinations for triggering infections. The
design made it impossible to establish identical routines in all
centres and countries for microbiological examinations.
Further, it was not possible to perform uniform examinations
of antibodies to triggering infections or T cell proliferation
tests. Twenty five synovial fluids were available for examina-
tion, but none was positive either by Chlamydia trachomatis-
specific amplification using the Abbott LCR assay or by broad
range polymerase chain reaction (PCR)34 which, however, is
less sensitive than species-specific PCR.35 Our best approach
to explore the microbiological background was to examine
urine with LCR, but Chlamydia infection was only detected in
12/130 patients in whom urine was tested. Thus, the results
of this study must be interpreted under the understanding
that recruitment was designed to reflect the ‘‘real world’’
experience of diagnosis of ReA, where patients who present
with acute oligoarticular arthritis for which no other
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explanation such as sepsis or crystal arthritis is forthcoming
are likely to have ReA. This strategy seems to have been
successful, judging by the proportion of B27+ subjects in the
study.
B27+ subjects have been shown to have more severe ReA
than B272 subjects36 and thus more likely to present to
rheumatologists within 8 weeks of the onset of disease.37
However, analysis of the B27+ subjects as a separate subset
also failed to show the efficacy of antibiotics, although the
power of this analysis is evidently limited. The whole study
was originally powered to detect an effect of azithromycin
similar to that noted for lymecycline in Chlamydia induced
ReA. The proportion of patients with evidence of preceding
Chlamydia infection shown by PCR of urine was rather low,
and no conclusion can be derived from analysis of this
subgroup. In this sense the trial does not necessarily negate
the previous finding of Lauhio et al,18 but no other study has
positively supported its conclusions.
Several recent trials have tested ciprofloxacin; this is the
first to use azithromycin. The drug was used because it has
excellent activity against ReA associated organisms (particu-
larly Chlamydiae) and achieves high intracellular concentra-
tions—this may be important in ReA, which involves species
which are obligate or facultative intracellular organisms.
Lastly, its once weekly dosage lends itself particularly well to
prolonged administration. The drug was well tolerated with
few withdrawals due to adverse effects, although the number
of adverse events was considerably higher than in the placebo
group. One important consideration for the trial was the
danger of leaving Chlamydia infected patients untreated if
they were allocated to placebo treatment. For this reason all
patients received a single dose of azithromycin at entry,
because this is recognised as appropriate treatment for
genital tract Chlamydia infection, and there is no evidence
to suggest that short term treatment with antibiotics has any
influence on the course of ReA.
If the results in this trial (and other recent trials of the
same general kind) are valid, what are the implications for
our understanding of the pathogenesis of ReA? It might be
argued that arthritis is not maintained by persistent infec-
tion, and that the bacterial nucleic acids and antigens
repeatedly demonstrated in synovial fluid or synovium are
not relevant to pathogenesis.8 12–14 17 38–41 Instead infection
would be seen as a trigger of some form of autoimmune
disease, directed against unknown joint components or even
(in B27+ cases) HLA-B27 itself.42 However, it is also possible
that persistent infection does play a crucial part in
pathogenesis, but that the organisms triggering ReA enter a
state in which they have low susceptibility to antibiotics,
perhaps owing to very slow rates of multiplication.
Experimental evidence in Yersinia infection in rats suggests
that antibiotics given at any time, except immediately after
infection, prolong organism survival and excretion.43
In summary, this study does not support the use of a
prolonged course of antibiotics for the alleviation of ReA. This
is an important conclusion, because such treatment has
become commonplace, perhaps as a reasonable response to
the demonstration of organisms in the ReA joint. Instead
disease modifying drugs such as sulfasalazine44–46 and,
possibly, methotrexate may be justified in severe disease
which fails to resolve spontaneously, and there are now also
reports of efficacy of tumour necrosis factor blocking
compounds in chronic ReA.47 48
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